

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group

Rotterdam, The Netherlands

Received October 22, 2003; revised and accepted October 22, 2003.

May 1–3, 2003, Rotterdam, The Netherlands.

Congress chairmen: Tarlatzis (Gr), Fauser (Nl).

Scientific committee: J. Chang (USA), R. Azziz (USA), R. Legro (USA), D. Dewailly (Fr), S. Franks (UK), R. Tarlatzis (Gr), B. Fauser (Nl).

Invited discussants: A.

Balen (UK), Ph. Bouchard (Fr), E. Dahlgren (Sw), L. Devoto (Chi), E. Diamanti (Gr), A. Dunaif (USA), M. Filicori (It), R. Homburg (Is), L. Ibanez (Sp), J. Laven (Nl), D. Magoffin (USA), J. Nestler (USA), R. Norman (Aus), R. Pasquali (It), M. Pugeat (Fr), J. Strauss (USA), S. Tan (Can), A. Taylor (USA), R. Wild (USA), S. Wild (UK).

Invited discussants not present during the meeting: J. Chang (USA), D. Guzick (USA), D. Ehrmann (USA), R. Lobo (USA).

This symposium was financially sponsored by an unconditional grant from NV Organon and by ESHRE/ASRM.

Reprint requests: Bart C. J. M. Fauser, M.D., Ph.D., Center of Reproductive Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands (FAX: 31-10-4367306; E-mail: b.fauser@erasmusmc.nl).

0015-0282/04/\$30.00
doi:10.1016/j.fertnstert.2003.10.004

Since the 1990 National Institutes of Health–sponsored conference on polycystic ovary syndrome (PCOS), it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunction than those defined by the original diagnostic criteria. The 2003 Rotterdam consensus workshop concluded that PCOS is a syndrome of ovarian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology. PCOS remains a syndrome, and as such no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis. Its clinical manifestations may include menstrual irregularities, signs of androgen excess, and obesity. Insulin resistance and elevated serum LH levels are also common features in PCOS. PCOS is associated with an increased risk of type 2 diabetes and cardiovascular events. (*Fertil Steril*® 2004;81:19–25. ©2004 by American Society for Reproductive Medicine.)

Nearly 15 years have passed since the first international conference on polycystic ovary syndrome (PCOS) was held. During that initial meeting at the National Institutes of Health (NIH) in Bethesda, Maryland, there was considerable discussion with little consensus, although a questionnaire led to the current diagnostic criteria that stand today (see Table 1). Based on the majority opinion rather than clinical trial evidence, the following diagnostic criteria were put forth: clinical or biochemical evidence of hyperandrogenism, chronic anovulation, and exclusion of other known disorders (1). These criteria were an important first step toward standardizing diagnosis and led to a number of landmark randomized multicenter clinical trials in PCOS (2, 3). Since that time and as outlined during a number of subsequent international conferences (4), there has been a gradually increasing awareness that the clinical expression of PCOS may be broader than that defined by the 1990 NIH criteria.

Rotterdam Consensus on Diagnostic Criteria for PCOS

PCOS is a syndrome of ovarian dysfunction. Its cardinal features are hyperandrogenism and polycystic ovary morphology (5). Its clinical manifestations may include menstrual irregularities, signs of androgen excess, and obesity.

PCOS is associated with an increased risk of type 2 diabetes (6, 7). Since the 1990 NIH-sponsored conference on PCOS, it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunction than those defined by the original diagnostic criteria (Table 1). It is now recognized that women with regular cycles and hyperandrogenism and/or polycystic ovaries (PCO) may have the syndrome (8–10). It has also been recognized that some women with the syndrome will have PCO without clinical evidence of androgen excess but will display evidence of ovarian dysfunction.

PCOS remains a syndrome and as such no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis. PCOS also remains a diagnosis of exclusion. Known disorders that mimic the PCOS phenotype should be excluded.

Diagnostic Criteria for Clinical Trials and Familial Studies

The above-mentioned diagnostic criteria may not be suitable for trials focusing on clinical outcomes in women with PCOS. For instance, trials focusing on pregnancy as an outcome may place greater emphasis on anovulation as the identifying symptom, rather

TABLE 1**Revised diagnostic criteria of polycystic ovary syndrome.**

1990 Criteria (both 1 and 2)

1. Chronic anovulation and
2. Clinical and/or biochemical signs of hyperandrogenism and exclusion of other etiologies.

Revised 2003 criteria (2 out of 3)

1. Oligo- or anovulation,
2. Clinical and/or biochemical signs of hyperandrogenism,
3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)

Note: Thorough documentation of applied diagnostic criteria should be done (and described in research papers) for future evaluation.

2003 Rotterdam PCOS consensus. *Fertil Steril* 2004.

than the presence of PCO or clinical hyperandrogenism. Similarly, trials seeking an improvement in hirsutism may deemphasize baseline ovulatory function and require some pathological terminal hair growth for entry. Moreover, women with chronic anovulation and hyperandrogenism and/or PCO appear to be at substantially greater risk for insulin resistance than those with hyperandrogenism and regular cycles (11, 12). Accordingly, it is essential that studies of the metabolic features of PCOS stratify affected women according to ovulatory function (i.e., chronic oligo-/amenorrhea vs. regular cycles).

Family studies are critical for understanding the spectrum of phenotypes and for identifying susceptibility genes for PCOS. More narrow diagnostic criteria may be used in family studies to identify affected individuals, such as the presence of PCO alone (13) or hyperandrogenemia per se (14). A rigid definition of PCOS based on the present or past proposed diagnostic criteria may hamper our understanding of this heterogeneous disorder.

Exclusion of Related Disorders

To establish the diagnosis of PCOS, it is important to exclude other disorders with a similar clinical presentation, such as congenital adrenal hyperplasia, Cushing's syndrome, and androgen-secreting tumors. Exclusion of 21-hydroxylase deficient nonclassic adrenal hyperplasia (NCAH) can be performed using a basal morning 17-hydroxyprogesterone level, with cutoff values ranging between 2 and 3 ng/mL (15). Some participants felt that the routine screening of hyperandrogenic patients for NCAH should take into account the prevalence of this autosomal recessive disorder in the population under study.

The routine exclusion of thyroid dysfunction in patients deemed to be hyperandrogenic was felt to have limited value, as the incidence of this disorder among these patients is no higher than that in normal women of reproductive age. However, because screening for thyroid disorders may be advisable in all women of reproductive age, the routine

measurement of TSH in the hyperandrogenic patient need not be discouraged.

The initial workup in women presenting with oligo/anovulation may also include the assessment of serum FSH and E₂ levels to exclude hypogonadotropic hypogonadism (i.e., central origin of ovarian dysfunction) or premature ovarian failure characterized by low E₂ and high FSH concentrations, according to World Health Organization (WHO) classification (16, 17). PCOS is part of the spectrum of normogonadotropic normoestrogenic anovulation (WHO 2) (5, 18). It should be emphasized, however, that serum LH concentrations are frequently elevated in these patients, as will be discussed later.

Most participants felt that the routine measurement of PRL in the evaluation of hyperandrogenic patients should be performed to exclude hyperprolactinemia, with a caveat that many hyperandrogenic patients may have PRL levels in the upper normal limit or slightly above normal.

Finally, syndromes of severe insulin resistance (e.g., for the diagnosis of the hyperandrogenic-insulin resistant-acanthosis nigricans, or HAIRAN, syndrome) (19), Cushing's syndrome (20), androgen-secreting neoplasms (20, 21), or high-dose exogenous androgens (22) should be excluded if clinically suspected.

Hyperandrogenism

Clinical phenotyping of PCOS involves determining the presence of clinical and/or biochemical androgen excess (hyperandrogenism), while excluding related disorders.

Clinical Hyperandrogenism: Most participants felt that the primary clinical indicator of androgen excess is the presence of hirsutism (23). However, the following issues should be emphasized:

- Normative data in large populations are still lacking.
- The assessment of hirsutism is relatively subjective.
- Few physicians in clinical practice actually use standardized scoring methods.
- Hirsutism is often treated well before the patient is ever evaluated endocrinologically.
- Hirsutism may be significantly less prevalent in hyperandrogenic women of East Asian origin (24) or in adolescence (25).

The sole presence of acne was also felt to be a potential marker for hyperandrogenism, although studies are somewhat conflicting regarding the exact prevalence of androgen excess in these patients (26). The sole presence of androgenic alopecia as an indicator of hyperandrogenism has been less well studied. However, it appears to be a relatively poor marker of androgen excess, unless present in the oligo-ovulatory patient (27). Overall, the clinical evidence of hyperandrogenism is an important feature of patients with PCOS, notwithstanding the above-mentioned limitations.

Biochemical Hyperandrogenism: Most patients with PCOS have evidence of hyperandrogenemia, and recent ob-

servations suggest that circulating androgen levels may also represent an inherited marker for androgen excess (14). However, it was clearly denoted that a proportion of patients with PCOS may not demonstrate an overt abnormality in circulating androgens (5, 28–31).

The limitations of defining androgen excess by the measurement of circulating androgen levels were felt to be due in part to the inaccuracy and variability of the laboratory methods of measurement that are often used (32–34):

- There are multiple androgens that may not be considered (35).
- There is wide variability in the normal population.
- Normative ranges have not been well-established using well-characterized control populations.
- Age and body mass index (BMI) have not been considered when establishing normative values for androgen levels (36, 37).
- Little normative data are present on adolescent and older women.
- Androgens are suppressed more rapidly by hormonal suppression than other clinical features and may remain suppressed even after discontinuation of hormonal treatment.

Notwithstanding these limitations, it was felt that the measurement of free T or the free T (free androgen) index (34) were the more sensitive methods of assessing hyperandrogenemia (38, 39). Recommended methods for the assessment of free T included equilibrium dialysis (33, 34), calculation of free T from the measurement of sex hormone-binding globulin and total T, or ammonium sulfate precipitation (40). It was the uniform impression that currently available direct assays for free T have limited value, particularly in the evaluation of the hyperandrogenic woman.

It was noted that measurement of total T only may not be a very sensitive marker of androgen excess. A small fraction of patients with PCOS may have isolated elevations in dehydroepiandrosteronesulphate (DHEAS) levels. Some felt that the measurement of total T and DHEAS had some value in detecting a patient with an androgen-secreting tumor (41), although more recent data suggest that the best predictor of these neoplasms is the clinical presentation (42).

Finally, little data are available on the value of routinely measuring androstenedione in hyperandrogenic patients (5), although it was noted that it might be somewhat more elevated in patients with 21-hydroxylase-deficient nonclassical adrenal hyperplasia than in patients with PCOS. Nonetheless, the paucity of normative and clinical data with androstenedione precluded its recommendation for the routine assessment of hyperandrogenemia.

Polycystic Ovaries (PCO)

Workshop participants felt that PCO should now be considered as one of the possible criteria for PCOS (see Table 1). According to the available literature (18, 43, 44), the criteria having sufficient specificity and sensitivity to define

PCO are the following: “Presence of 12 or more follicles in each ovary measuring 2–9 mm in diameter, and/or increased ovarian volume (>10 mL)” (for a review, see 45). The subjective appearance of PCO should not be substituted for this definition. The follicle distribution should be omitted as well as the increase in stromal echogenicity and volume. Although increased stromal volume is a feature of PCO (46), it has been shown that the measurement of the ovarian volume is a good surrogate for the quantification of stromal volume in clinical practice (47). This definition does not apply to women taking the oral contraceptive pill, since its use modifies ovarian morphology in normal women and putatively in women with PCO (48). Only one ovary fitting this definition is sufficient to define PCO. If there is evidence of a dominant follicle (>10 mm) or a corpus luteum, the scan should be repeated during the next cycle. The presence of an abnormal cyst or ovarian asymmetry (which may suggest a homogeneous cyst) necessitates further investigation.

A woman having PCO in the absence of an ovulatory disorder or hyperandrogenism (“asymptomatic” PCO) should not be considered as having PCOS until more is known regarding the clinical presentation (49). In addition to its role in the definition of PCOS, ultrasound is helpful to predict fertility outcome of clomiphene citrate (50) and the risk of ovarian hyperstimulation syndrome (OHSS) and to assist in deciding whether the *in vitro* maturation of oocytes is desirable (51).

It is recognized that the appearance of PCO may be seen in women before undergoing ovarian stimulation for IVF in the absence of overt signs of the PCOS. These ovaries, when stimulated, behave like the ovaries of women with PCOS and are at increased risk for hyperstimulation and OHSS (52).

In addition, ultrasound provides the opportunity to screen for endometrial hyperplasia in these patients. The following technical recommendations should be highlighted:

- State-of-the-art equipment is required and should be operated by appropriately trained personnel.
- Whenever possible, the transvaginal approach should be used, particularly in obese patients.
- Regularly menstruating women should be scanned in the early follicular phase (cycle days 3–5). Oligo-/amenorrhoeic women should be scanned either at random or between days 3 and 5 after a progestin-induced withdrawal bleeding.
- Calculation of ovarian volume is performed using the simplified formula for a prolate ellipsoid ($0.5 \times \text{length} \times \text{width} \times \text{thickness}$) (53).
- Follicle number should be estimated both in longitudinal and antero-posterior cross-sections of the ovaries. The size of follicles <10 mm should be expressed as the mean of the diameters measured on the two sections.

TABLE 2

Summary of 2003 polycystic ovary syndrome (PCOS) consensus regarding screening for metabolic disorders.

Summary of consensus

1. No tests of insulin resistance are necessary to make the diagnosis of PCOS, nor are they needed to select treatments.
2. Obese women with PCOS should be screened for the metabolic syndrome, including glucose intolerance with an oral glucose tolerance test.
3. Further studies are necessary in nonobese women with PCOS to determine the utility of these tests, although they may be considered if additional risk factors for insulin resistance, such as a family history of diabetes, are present.

2003 Rotterdam PCOS consensus. *Fertil Steril* 2004.

Insulin Resistance

Insulin resistance is associated with reproductive abnormalities in women with PCOS (see also Table 2). Improving insulin sensitivity through both lifestyle and pharmacological intervention can ameliorate these abnormalities. Insulin resistance, defined as decreased insulin-mediated glucose utilization, is commonly found in the larger population (10%–25%) when sophisticated dynamic studies of insulin action are performed (54). However, the criteria for selecting an abnormal cutoff point vary. Insulin resistance in women with PCOS appears even more common (up to 50%), both in obese and nonobese women (55). Reports of the prevalence on insulin resistance in women with PCOS vary depending on the sensitivity and specificity of the tests employed and the heterogeneity of PCOS.

There is currently no validated clinical test for detecting insulin resistance in the general population. Dynamic invasive tests such as the euglycemic clamp and frequently sampled glucose tolerance test are research procedures because of their intensive use of time and resources. Calculated indices based on fasting levels of insulin and glucose correlate well with dynamic tests of insulin action. However, there are multiple flaws that limit their widespread clinical use, including changes in beta-cell function with the development of diabetes (which alters the sensitivity of the tests), normal physiologic fluctuation in insulin levels, and the lack of a standardized universal insulin assay.

Other consensus conferences also recommended against screening for insulin resistance in both the general population and in high-risk populations because of these concerns and concerns regarding the value of these tests to predict clinical events (56). Instead, criteria have been developed for defining a metabolic syndrome, which includes components associated with the insulin resistance syndrome, including centripetal obesity, hypertension, fasting hyperglycemia, and dyslipidemia (Table 3) (57).

Other groups have recommended adding an oral glucose tolerance test (OGTT) to these fasting blood tests to evaluate

TABLE 3

Criteria for the metabolic syndrome in women with polycystic ovary syndrome. (Three of five qualify for the syndrome.)

Risk factor	Cutoff
1. Abdominal obesity (waist circumference)	>88 cm (>35 inch)
2. Triglycerides	≥150 mg/dL
3. HDL-C	<50 mg/dL
4. Blood pressure	≥130/≥85
5. Fasting and 2-h glucose from oral glucose tolerance test	110–126 mg/dL and/or 2-h glucose 140–199 mg/dL

2003 Rotterdam PCOS consensus. *Fertil Steril* 2004.

the 2-hour glucose level after a 75-g oral glucose challenge for glucose intolerance (WHO criteria, impaired glucose tolerance [IGT] >140 mg/dL to 199 mg/dL) (58, 59). IGT has long been recognized as a major risk factor for diabetes (60), and recent studies have shown that progression to diabetes in individuals with IGT can be delayed by lifestyle changes and pharmacological intervention (61, 62). Additionally, IGT identifies individuals at risk for excess mortality, especially women (63, 64). Given the high prevalence of IGT and type 2 diabetes as diagnosed by the OGTT among obese women with PCOS, it is prudent to screen obese women (BMI >27 kg/m²) with PCOS with an OGTT (6, 65). Further studies of the prevalence of features of the metabolic syndrome are necessary in both lean and obese women with PCOS.

Currently, there are scant data to indicate that markers of insulin resistance predict responses to treatment (3, 39, 66). Therefore, the role of these markers in the diagnosis of PCOS, as well as in selecting specific treatments, is uncertain. Tests of insulin sensitivity are of greatest interest in research studies of [1] the pathophysiology of PCOS, [2] young adolescents with a combined history of low birth weight and excessive postnatal catch-up, [3] mechanisms of response to therapy, and [4] family phenotypes. Further studies to identify predictive factors or early response factors to treatments of PCOS are needed.

Luteinizing Hormone

Both the absolute level of circulating LH as well as its relation to FSH levels are significantly elevated in women with PCOS as compared with controls (67, 68). This is due to an increased amplitude and frequency of LH pulses (69). Elevated LH concentrations (above the 95th percentile of normal) can be observed in approximately 60% of women with PCOS (5, 18), whereas the LH/FSH ratio may be elevated in up to 95% of subjects (68) if women who have recently ovulated are excluded. LH levels may be influenced by the temporal relation to ovulation, which transiently nor-

malizes LH, by BMI (being higher in lean women with PCOS), as well as by the assay system used.

The potential negative actions of LH on human reproduction are highly controversial. Some investigators have suggested that high LH levels could have detrimental effects on oocyte maturity and fertilization (70), as well as result in lower pregnancy and higher miscarriage rates (71). However, other studies have shown no untoward actions of LH on oocyte and embryo quality or on fertilization, implantation, and pregnancy rates (72, 73). Reduction of endogenous LH levels with GnRH agonists also provided conflicting results as some studies have suggested that this maneuver could reduce miscarriage rates (74), while others have questioned this therapeutic effect (75, 76). LH levels or the administration of exogenous LH activity were not found to affect the chances of ovulation or achievement of pregnancy using clomiphene citrate (39, 49) or exogenous gonadotropins (77, 78).

Based on the aforementioned data, the panel felt that measurement of serum LH levels should not be considered necessary for the clinical diagnosis of PCOS. LH levels could be useful as a secondary parameter (especially in lean women with amenorrhea or in research). Additional research is needed to further clarify the clinical relevance of LH in PCOS and the potential effects of LH suppression with GnRH analogs or its enhancement through LH activity administration at different stages of follicular maturation.

Long-Term Health Risks

Women with PCOS have multiple risk factors for diabetes including obesity, a family history of type 2 diabetes, and abnormalities in insulin action (both insulin resistance and beta-cell dysfunction). There is now clear evidence that women with PCOS are at increased (3–7 times) risk of developing type 2 diabetes (6, 7, 11, 79, 80). There are several lines of evidence suggesting that women with PCOS are also at increased risk of cardiovascular disease (81). Insulin-resistant states are associated with greater than normal susceptibility to coronary heart disease, and women with PCOS have evidence of dyslipidemia (82–85) and markers of abnormal vascular function (86–88). However, limited epidemiological studies have shown no direct evidence of an increased incidence of coronary heart disease in middle-aged women with a history of PCOS (although the incidence of stroke is slightly increased) (89).

Women with PCOS are also thought to be at increased risk for endometrial cancer through chronic anovulation with unopposed estrogen exposure of the endometrium. However, epidemiological evidence to support this hypothesis is limited (90).

Currently, no firm conclusions can be drawn, but the following statements represent the consensus view that PCOS is associated with an increased risk of type 2 diabetes:

- The risk is greater in anovulatory women with PCO, in obese subjects, and in those with a family history of type 2 diabetes.
- The risk of cardiovascular disease is uncertain at present (89, 91). Limited epidemiological data have shown no increase in cardiovascular events, but two factors need to be borne in mind: The young age of the cohorts studied so far (around 55 years) and the possibility that unknown factor(s) may be present in PCOS that protect the heart in the face of other risk factors.

More research is required to [1] assess the level of risk, [2] enable identification of patients at risk, [3] provide longitudinal follow-up of PCOS cohorts into their sixties and beyond, and [4] determine the place, timing, and efficacy of interventional measures.

Although many questions remain to be answered, lifestyle changes (diet and exercise) should be strongly encouraged to reduce the risk of both type 2 diabetes and cardiovascular disease (37, 92–95).

References

1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, eds. *Polycystic ovary syndrome*. Boston: Blackwell Scientific, 1992: 377–84.
2. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. *N Engl J Med* 1998;338:1876–80.
3. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. *J Clin Endocrinol Metab* 2001;86:1626–32.
4. Chang RJ, Katz SE. Diagnosis of polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 1999;28:397–408.
5. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approaches to PCOS and other forms of anovulation. *Obstet Gynecol Surv* 2002;57: 755–67.
6. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 1999;84:165–9.
7. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care* 1999;22:141–6.
8. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. *Br Med J* 1986;293: 355–9.
9. Franks S. Polycystic ovary syndrome: a changing perspective (review). *Clin Endocrinol* 1989;31:87–120.
10. Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. *Am J Med* 2001;111:602–6.
11. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. *J Clin Endocrinol Metab* 1987;65:499–507.
12. Robinson S, Kiddy D, Gelding SV, Willis D, Nithyananthan R, Bush A, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. *Clin Endocrinol* 1993;39:351–5.
13. Carey AH, Chan KL, Short F, White D, Williamson R, Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. *Clin Endocrinol* 1993;38:653–8.
14. Legro RS, Driscoll D, Strauss JF III, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. *Proc Natl Acad Sci USA* 1998;95:14956–60.
15. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. *Fertil Steril* 1999;72:915–25.
16. ESHRE Capri Workshop Group. Anovulatory infertility. *Hum Reprod* 1995;10:1549–53.

17. Rowe PJ, Comhaire FH, Hargreave TB. Female partner. In: World Health Organization manual for the standardized investigation and diagnosis of the infertile couple. Cambridge: Cambridge University Press, 2000:40–67.
18. Van Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropin infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of PCOS. *Fertil Steril* 1997;67:452–8.
19. Moller DE, Cohen O, Yamaguchi Y, Azziz R, Grigorescu F, Eberle A, et al. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. *Diabetes* 1994;43:247–55.
20. Kreisberg RA. Clinical problem-solving. Half a loaf. *N Engl J Med* 1994;330:1295–9.
21. Waggoner W, Boots LR, Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. *Gynecol Endocrinol* 1999;13:394–400.
22. Pache TD, Chadha S, Gooren LJ, Hop WC, Jaarsma KW, Dommerholt HB, et al. Ovarian morphology in long-term androgen-treated female-to-male transsexuals. A human model for the study of PCOS? *Histopathology* 1991;19:445–52.
23. Diamanti-Kandarakis E, Koulie CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek Island of Lesbos: a hormonal and metabolic profile. *J Clin Endocrinol Metab* 1999;84:4006–11.
24. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism in insulin resistance in the polycystic ovary syndrome? *Am J Obstet Gynecol* 1992;167:1807–12.
25. Ruutiainen K, Erkkola R, Gronroos MA, Irjala K. Influence of body mass index and age on the grade of hair growth in hirsute women of reproductive ages. *Fertil Steril* 1998;50:260–5.
26. Slayden SM, Moran C, Sams WM Jr, Boots LR, Azziz R. Hyperandrogenemia in patients presenting with acne. *Fertil Steril* 2001;75:889–92.
27. Futterweit W, Dunaif A, Yeh C, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. *J Med Acad Dermatol* 1988;19:831–6.
28. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women in the Southeastern United States: a prospective study. *J Clin Endocrinol Metab* 1988;83:3078–82.
29. Pugeat M, Nicolas MH, Craves JC, Alvarado-Dubost C, Fimbel S, Cechaud H, et al. Androgens in polycystic ovarian syndrome. *Ann NY Acad Sci* 1993;687:124–35.
30. Balen AH, Conway GS, Kalsas G, Techtrasak K, Manning PJ, West C, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. *Hum Reprod* 1995;10:2107–11.
31. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. *J Clin Endocrinol Metab* 2000;85:2434–8.
32. Boots LR, Potter S, Potter HD, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. *Fertil Steril* 1998;69:286–92.
33. Rosner W. Errors in the measurement of plasma free testosterone. *J Clin Endocrinol Metab* 1997;82:2014–5.
34. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666–72.
35. Rittmaster RS. Androgen conjugates: physiology and clinical significance. *Endocrine Rev* 1993;14:121–32.
36. Bili H, Laven J, Imani B, Eijkemans MJ, Fauser BC. Age related differences in features associated with PCOS in normogonadotrophic oligo-amenorrheic infertile women of reproductive years. *Eur J Endocrinol* 2001;145:749–55.
37. Moran C, Knochenhauer E, Boots LR, Azziz R. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. *Fertil Steril* 1999;71:671–4.
38. Cibula D, Hill M, Starka L. The best correlation of the new index of hyperandrogenism with the grade of increased hair. *Eur J Endocrinol* 2000;143:405–8.
39. Imani B, Eijkemans MJ, de Jong FH, Payne NN, Bouchard P, Giudice LC, et al. Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotrophic oligoamenorrheic infertility. *J Clin Endocrinol Metab* 2000;85:676–82.
40. Tremblay RR, Dube JY. Plasma concentration of free and non-TeBG bound testosterone in women on oral contraceptives. *Contraception* 1974;10:599–605.
41. Meldrum DR, Abraham GE. Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. *Obstet Gynecol* 1979;53:36–43.
42. Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. *N Engl J Med* 1994;331:968–73.
43. Pache TD, Hop WC, Wladimiroff JW, Schipper J, Fauser BC. How to discriminate between normal and polycystic ovaries. *Radiol* 1992;17:589–93.
44. Jonard S, Robert Y, Cortet C, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? *Hum Reprod* 2003;18:598–603.
45. Balen A. Ovulation induction for polycystic ovary syndrome. *Hum Fertil (Camb.)* 2003;3:106–11.
46. Bucket WM, Bouzayen R, Watkin KL, Tulandi T, Tan SL. Ovarian stromal echogenicity in women with normal and polycystic ovaries. *Hum Reprod* 2003;18:598–603.
47. Dewailly D, Robert Y, Helin I, Ardaens Y, Thomas P, Lemaître L, et al. Ovarian stromal hypertrophy in hyperandrogenic women. *Clin Endocrinol* 1994;41:557–62.
48. Christensen JT, Boldsoen J, Westergaard JG. Ovarian volume in gynecologically healthy women using contraception or using IUD. *Acta Obstet Gynecol Scand* 1997;76:784–9.
49. Dewailly D. Definition and significance of polycystic ovaries: In: Hyperandrogenic states and hirsutism. *Bull Clin Obstet Gynaecol* 1997;11:349–68.
50. Imani B, Eijkemans MJ, te Velde ER, Habbema D, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate ovulation induction in normogonadotrophic oligoamenorrheic infertility. *Fertil Steril* 2002;77:91–7.
51. Tan SL, Child TJ. In-vitro maturation of oocytes from unstimulated polycystic ovaries. *RBM Online* 2002;4:597–600.
52. McDougall MJ, Tan SL, Jacobs HS. IVF and the ovarian hyperstimulation syndrome. *Hum Reprod* 1992;5:597–600.
53. Swanson M, Sauerbrei EE, Cooperberg PL. Medical implications of ultrasonically detected polycystic ovaries. *J Clin Ultrasound* 1981;9:219–22.
54. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. *J Clin Invest* 1997;30:1166–73.
55. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. *Diabetes* 1989;38:1165–74.
56. American Diabetic Association. Consensus Development Conference on Insulin Resistance. *Diabetes Care* 1998;21:310–4.
57. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. *J Am Med Assoc* 2001;285:2486–97.
58. Bloomgarden ZT. American Association of Clinical Endocrinologists (AAACE) consensus conference on the insulin resistance syndrome. *Diabetes Care* 2003;26:1297–1303.
59. Bloomgarden ZT. American Association of Clinical Endocrinologists consensus conference on the insulin resistance syndrome. *Diabetes Care* 2003;26:933–39.
60. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome. *Hum Reprod* 2001;9:1995–8.
61. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes* 2002;51:2796–803.
62. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403.
63. Anonymous. Glucose tolerance and mortality: comparison of WHO and American diabetes association diagnostic criteria. *Lancet* 1999;354:617–21.
64. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The funagata diabetes study. *Diabetes Care* 1999;22:920–4.
65. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 1999;84:165–9.
66. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. *J Clin Endocrinol Metab* 2000;85:139–46.

67. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD. Serum bioactive and immunoreactive LH and FSH levels in women with cycle abnormalities, with or without PCOD. *J Clin Endocrinol Metab* 1991;73:811–7.
68. Taylor AE, McCourt B, Martin K, Anderson EJ, Adams J, Schoebfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. *J Clin Endocrinol Metab* 1997;82:2248–56.
69. Waldstreicher J, Santoro NF, Hall HJE, Filicori M, Crowley WF. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence of partial gonadotroph desensitization. *J Clin Endocrinol Metab* 1988;66:165–72.
70. Tarlatzis BC, Grimbizis G, Pournaropoulos F, Bontis J, Spanos E, Mantalenakis S. The prognostic value of basal LH:FSH ratio in the treatment of patients with PCOS by assisted reproduction. *Hum Reprod* 1995;10:2545–9.
71. Balen AH, Tan SL, McDougall J, Jacobs HS. Miscarriage rates following IVF are increased in women with PCO and reduced pituitary desensitization with buserelin. *Hum Reprod* 1993;8:959–64.
72. Gordon UD, Harrison RF, Hennelly B. A randomized prospective assessor-blind evaluation of LH dosage and IVF. *Fertil Steril* 2001;75:324–31.
73. Mendoza C, Ruiz E, Ortega E, Cremades N, Martinez F, Bernabeu R, et al. Follicular fluid markers of oocyte developmental potential. *Hum Reprod* 2002;17:1017–22.
74. Homburg R, Levy T, Berkovitz D, Farchi J, Feldberg D, Ashkenazi J, et al. GnRH agonist reduces the miscarriage rate for pregnancies achieved in women with PCOS. *Fertil Steril* 1993;59:527–31.
75. Clifford CK, Rai R, Watson H, Franks S, Regan L. Does suppressing LH secretion reduce the miscarriage rate? Results of a randomised controlled trial. *Br Med J* 1996;312:1508–11.
76. Hughes E, Collins J, Vandekerckhove P. GnRH analogue as an adjunct to gonadotropin therapy for clomiphene resistant PCOS (Cochrane review). *The Cochrane Library* 2000, Oxford Update software.
77. Al-Inani H, Aboughar M, Mansour R, Serour G. Meta-analysis of recombinant versus urinary-derived FSH: an update. *Hum Reprod* 2003;18:305–13.
78. Mulders AG, Eijkemans MJ, Imani B, Fauser BC. Prediction of chances for success and complications in gonadotrophin ovulation induction in normogonadotropic anovulatory infertility. *RBM Online* 2003;7:48–56.
79. Dahlgren E, Johansson S, Lindstedt G. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. *Fertil Steril* 1992;57:505–13.
80. Wild S, Pierpoint T, McKeigue P, Jacobs HS. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. *Clin Endocrinol* 2000;52:595–600.
81. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction—evaluated from a risk factor model based on a prospective study of women. *Acta Obstet Gynecol Scand* 1992;71:599–604.
82. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. *Clin Endocrinol* 1992;37:119–25.
83. Robinson S, Henderson AD, Gelding SV. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. *Clin Endocrinol* 1996;44:277–84.
84. Talbott E, Clerici A, Berga SL. Adverse lipid and coronary heart risk profiles in young women with polycystic ovary syndrome: results of a case-control study. *J Clin Epidemiol* 1998;51:415–22.
85. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. *Am J Med* 2001;117:607–13.
86. Talbott EO, Guzick DS, Sutton-Tyrrell K. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. *Arterio Thromb Vasc Biol* 2000;20:2414–21.
87. Paradisi G, Steinberg HO, Hempfling A. Polycystic ovary syndrome is associated with endothelial dysfunction. *Circulation* 2001;103:1410–15.
88. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF II, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003;88:2562–8.
89. Wild RA. Long-term health consequences of PCOS. *Hum Reprod Update* 2002;8:231–41.
90. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. *Lancet* 2003;361:1810–2.
91. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? *Endocrine Rev* 2003;24:302–12.
92. Kiddy DS, Hamilton-Fairley D, Bush A, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. *Clin Endocrinol* 1992;36:105–11.
93. Clark AM, Ledger W, Galletly C. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Hum Reprod* 1995;10:2705–12.
94. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. *J Clin Endocrinol Metab* 1999;84:1470–4.
95. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003;88:812–9.